A research analyst receives confidential details regarding a failed clinical trial directly from a biopharmaceutical firm's lead scientist, who breached a non-disclosure agreement by sharing the information. Rather than trading shares of the biopharmaceutical firm itself, the analyst purchases put options on an independent key supplier whose revenues depend almost entirely on the biopharmaceutical firm's drug production. The analyst also informs a colleague, who subsequently purchases put options on the supplier. Neither individual provided monetary compensation to the scientist. Based on federal securities law governing insider trading and misuse of material nonpublic information, which of the following statements correctly evaluates the legal liability of the parties involved?
- Both the analyst and the colleague can be held liable for insider trading because trading options on an economically connected supplier using misappropriated material nonpublic information violates federal insider trading provisions.Answer
- BOnly the lead scientist can be held liable because insider trading violations require trading in the primary issuing firm's equity securities and direct monetary compensation between tipper and tippee.
- CThe colleague is completely exempt from tippee liability because tippee status strictly requires receiving confidential information directly from an officer or director of the subject company.
- DNeither the analyst nor the colleague committed an insider trading violation because buying put options on a third-party supplier constitutes acceptable market arbitrage rather than prohibited trading.